Sort
10,766 grants matching “checkpoint inhibitor”
Radiogenomic Credentialing of Head and Neck Cancer Models
$583,802Mukund Seshadri · Roswell Park Cancer Institute Corp · R01 · FY2023 · CA
Glycosylation and Immune Evasion in Urologic Tumors
$583,786Sharon Pitteri · Stanford University · U01 · FY2023 · CA
Cardioprotective Therapy for Doxorubicin Using iPSC Microtissue and CRISPR Screening
$583,765Joseph C Wu · Stanford University · R01 · FY2024 · HL
Dissecting the role of hypoxia in T cell differentiation in cancer
$583,740Greg M. Delgoffe · University Of Pittsburgh At Pittsburgh · R01 · FY2024 · CA
The NOTCH Signaling Pathway in Large Vessel Vasculitis
$583,711Cornelia M Weyand · Mayo Clinic Rochester · R01 · FY2022 · HL
Development of Novel Spontaneous HPV Cervicovaginal Carcinoma Models for Cancer Immunotherapy
$583,657T.-C. Wu · Johns Hopkins University · R01 · FY2020 · CA
(8) Genetics of Immune Related Adverse Events and Response to Immunotherapy
$583,603Elad Ziv · University Of California, San Francisco · R01 · FY2022 · CA
Exploring DNA damage response pathways as targets for cancer therapy
$583,430Junjie Chen · University Of Tx Md Anderson Can Ctr · R35 · FY2022 · CA
PAG is a novel target in immunotherapy
$583,390Adam Mor · Columbia University Health Sciences · R01 · FY2020 · AI
Immune correlates of LTBI in HIV-exposed infants
$583,360Savita Pahwa · University Of Miami School Of Medicine · R01 · FY2022 · AI
Development of Novel Spontaneous HPV Cervicovaginal Carcinoma Models for Cancer Immunotherapy
$583,258T.-C. Wu · Johns Hopkins University · R01 · FY2021 · CA
Overcoming the immune-suppressive tumor microenvironment through in situ vaccination nanotechnology.
$583,253Nicole Franziska Steinmetz · University Of California, San Diego · U01 · FY2021 · CA
Finding the optimal balance of immunotherapy efficacy and toxicity.
$583,185David Eric Gerber · Ut Southwestern Medical Center · U01 · FY2021 · AI
TGX-1214 - Combination Strategy for the Treatment of Advanced Pancreatic Cancer
$583,071Gerardo Guillermo Mackenzie · University Of California At Davis · R01 · FY2023 · CA
Phase II Clinical Development of Galectin-3 Inhibition and Anti-PD-1: Immune Monitoring and Tumor Response
$582,888Brendan D Curti · Providence Portland Medical Center · R01 · FY2023 · CA
Role of IRF2 in cancer immune evasion and immunotherapy
$582,872Kenneth L Rock · Univ Of Massachusetts Med Sch Worcester · R01 · FY2020 · CA
Role of IRF2 in cancer immune evasion and immunotherapy
$582,872Kenneth L Rock · Univ Of Massachusetts Med Sch Worcester · R01 · FY2021 · CA
Overcoming hypoxic resistance to anti-cancer therapy
$582,714Nicholas C Denko · Ohio State University · R01 · FY2025 · CA
Overcoming hypoxic resistance to anti-cancer therapy
$582,714Nicholas C Denko · Ohio State University · R01 · FY2021 · CA
Drugging EBNA1 to Treat EBV-Associated Cancers
$582,466Paul M. Lieberman · Wistar Institute · R01 · FY2021 · CA
TOWARD TRANSLATION OF NANFORMULATED PACLITAXEL-PLATINUM COMBINATION
$582,405Alexander V Kabanov · Univ Of North Carolina Chapel Hill · R01 · FY2024 · CA
Glycosylation and Immune Evasion in Urologic Tumors
$582,341Sharon Pitteri · Stanford University · U01 · FY2021 · CA
Modulation of the tumor microenvironment with probiotic therapies
$582,197Tal Danino · Columbia Univ New York Morningside · R01 · FY2021 · CA
Targeting STAT3 for the Treatment of CDK4/6 Inhibitor Resistant Advanced Estrogen Receptor Positive Breast Cancer Patients
$581,711Khandan Keyomarsi · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA
Drugging EBNA1 to Treat EBV-Associated Cancers
$581,554Troy E Messick · Wistar Institute · R01 · FY2025 · CA